Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03971071 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache
A Phase 4 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 4
- Development phase
- 620
- Enrollment target
NCT03971071: Completed Phase 4 study, sponsored by Amgen.
NCT03971071 is a Phase 4 study that has completed, run by Amgen. The registered enrollment target is 620 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (20% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03971071, a Phase 4 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 620 participants
- Enrollment target
Study Summary
Study 20170703 is a phase 4, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of erenumab against placebo in participants with chronic migraine (CM) who have a history of at least 1 preventive treatment failure and are diagnosed with medication overuse headache (MOH).
Primary Outcome
Absence of MOH at month 6 was defined as mean monthly acute headache medication days (AHMD) \< 10 days over months 4, 5, and 6 (weeks 13 through 24) or mean monthly headache days \< 14 days over months 4, 5, and 6 (weeks 13 through 24) of the DBTP where an AHMD was defined as a calendar day in which the participant took at least 1 acute headache medication.
Interventions
- DRUG Placebo
- DRUG Erenumab 70 mg
- DRUG Erenumab 140 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 620 participants |
| Start Date | 2019-10-07 |
| Est. Completion | 2023-06-13 |
| Phase | Phase 4 |
What the finished NCT03971071 record still lists
NCT03971071 is an interventional study that assigns participants to a tested intervention. The registered 620 participants enrollment target is mid-sized for trials with a published cap, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (20% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03971071 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03971071 about?
NCT03971071 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache". Study 20170703 is a phase 4, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of erenumab against placebo in participants with chronic migraine (CM) who have a history of at least 1 preventive treatment failure and are diagnosed with medication o...
What is the current status of trial NCT03971071?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 620 participants. The study started on 2019-10-07. Estimated completion is 2023-06-13.
What interventions are being tested in trial NCT03971071?
The interventions under investigation include: Placebo (DRUG), Erenumab 70 mg (DRUG), Erenumab 140 mg (DRUG).
Who is sponsoring clinical trial NCT03971071?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03971071's enrollment target sits among peer trials
620 131st of 2000 higher than 1,870 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02282969 · 620 participants
PCORI-CER-1306-03385 Lung Cancer Screening Decision Aid Development and Testing
- NCT02838836 · 620 participants
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
- NCT05538910 · 620 participants · NA
Defining Neurobiological Links Between Substance Use and Mental Illness
- NCT05822466 · 620 participants · NA
Virtual Tai ji Quan Exercise to Prevent Falls in Older Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI